Nanopublication

ID

http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU
Formats

Content

@prefix biolink: <https://w3id.org/biolink/vocab/> .
@prefix ns1: <https://w3id.org/np/o/ntemplate/> .
@prefix this: <http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU> .
@prefix sub: <http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU#> .
@prefix schema: <https://schema.org/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix orcid: <https://orcid.org/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: a np:Nanopublication;
    np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo .
}

sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_3393> biolink:category biolink:Disease .
  
  sub:association a rdf:Statement;
    rdf:object <http://purl.obolibrary.org/obo/DOID_3393>;
    rdf:predicate biolink:treats;
    rdf:subject <https://identifiers.org/drugbank:DB00953>;
    rdfs:label "\"Rizatriptan benzoate tablets are contraindicated in patients with: * Ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), or other significant underlying cardiovascular disease  [see Warnings and Precautions ( 5.1 * Coronary artery vasospasm including Prinzmetal's angina  [see Warnings and Precautions ( 5.1 * History of stroke or transient ischemic attack (TIA)  [see Warnings and Precautions ( 5.4 * Peripheral vascular disease (PVD)  [see Warnings and Precautions ( 5.5 * Ischemic bowel disease  [see Warnings and Precautions ( 5.5 * Uncontrolled hypertension  [see Warnings and Precautions ( 5.8 * Recent use (i.e., within 24 hours) of another 5-HT 1 [see Drug Interactions ( 7.2 7.3 * Hemiplegic or basilar migraine. * Concurrent administration or recent discontinuation (i.e., within 2 weeks) of a MAO-A inhibitor  [see Drug Interactions ( 7.5 12.3 * Hypersensitivity to rizatriptan benzoate tablets or rizatriptan benzoate orally disintegrating tablets (angioedema and anaphylaxis seen)  [see Adverse Reactions ( 6.2 * History of ischemic heart disease or coronary artery vasospasm ( 4 * History of stroke or transient ischemic attack ( 4 * Peripheral vascular disease ( 4 * Ischemic bowel disease ( 4 * Uncontrolled hypertension ( 4 * Recent (within 24 hours) use of another 5-HT 1 4 * Hemiplegic or basilar migraine ( 4 * MAO-A inhibitor used in the past 2 weeks ( 4 * Hypersensitivity to rizatriptan benzoate( 4\"";
    biolink:provided_by <https://w3id.org/um/NeuroDKG>;
    biolink:relation schema:MedicalContraindication .
  
  <https://identifiers.org/drugbank:DB00953> biolink:category biolink:Drug .
}

sub:provenance {
  sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}

sub:pubinfo {
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
    npx:hasSignature "hpr6RALm/XiZ728FefzqvgvfH47zAddRv2y/RB5akx6Io8Bs21nKstq9xcPjflUbDg8KkCdRtsDSbM8ry733FIjrCUtQN5nsY9N5i0B/1HW4PgRADCyPdyvD97FIMhoSFuhCkwvt+1dZ/fUDPGvIAQSh0AbocjYd2iMXgoIksvA=";
    npx:hasSignatureTarget this: .
  
  this: dct:created "2021-08-23T18:05:19.392+02:00"^^xsd:dateTime;
    dct:creator orcid:0000-0002-1468-3557;
    ns1:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM>;
    ns1:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM>;
    ns1:wasCreatedFromTemplate <http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY> .
}